Skip to content
Search

Latest Stories

Submit Guest Post

UK to oppose Sunil Bharti Mittal move to raise BT stake: Report

According to the report, the UK government believes sovereign control over “critical national infrastructure” must be maintained.

Sunil Mittal

Indian billionaire Sunil Bharti Mittal. (Photo: Getty Images)

AFP via Getty Images

THE BRITISH government will oppose any move by Indian billionaire Sunil Bharti Mittal to increase his stake in telecoms group BT Group, the Financial Times reported on Thursday, citing people familiar with the matter.

According to the report, the UK government believes sovereign control over “critical national infrastructure” must be maintained.


Reuters reported last week that Bharti Enterprises was exploring the possibility of increasing its stake in BT to just below the threshold that would trigger a full takeover offer for the British telecoms group.

A Bharti spokesperson had said the company is pleased with its current 24.95 per cent shareholding and “currently has no plans to increase its stake.”

In September, Mittal, founder and chairman of Bharti Enterprises, and Gopal Vittal, vice-chairman and managing director of Bharti Airtel, joined the BT board as non-independent non-executive directors.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less